Altimmune, Inc. (ALT)
$2.43-5.08%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV5.5%–472.8%
- Market cap
- $214M
- Beta
- 0.18
- P/E (TTM)
- -3.12
- IV-%ile
- 32
- IV ATM
- 74.9%
- Short % float
- 52.63%
- Days to cover
- 10.5
- SI change
- -11.0%
- 1W
- -8.99%
- 1M
- -26.36%
- vs SPY 1W
- -8.85%
- vs SPY 1M
- -28.87%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on ALT?
- LOPJLB’s latest quantitative signal on Altimmune, Inc. (ALT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALT in?
- Altimmune, Inc. (ALT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Altimmune, Inc. (ALT) do?
- Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non…